Understanding the Dynamics of Drug Expenditure
Shares, Levels, Compositions, and Drivers
Institute Report
Jul 11, 2017

This report describes the dynamic changes in the composition of drug expenditure over the period 1995 to 2015 for five developed countries—France, Germany, Japan, the United Kingdom, and the United States. Over the past 20 years, therapies that once dominated spending are now dramatically less important, while other entirely new therapies have risen to a significant share of spending.

Key insights include:

Nominal drug expenditure measured at invoice price level has risen substantially over the past 20 years across all countries analyzed, though less so when normalized for economic and population growth.

When composition of drug expenditure is examined, the classes that dominated spending 20 years ago have shrunk considerably as innovation and product lifecycles shift costs downward.

Older therapies have declining importance as many have lost patent protection and costs have reduced considerably, while others have seen continuous innovation and have risen in share of spending.

Across all five countries, some common patterns emerge in terms of the therapy areas that now make up the large portion of spending and those that have declined. That said, each country has a distinct set of dynamics, spending compositions, and underlying clinical, disease, and policy drivers.

You may also be interested in
Contact Us
Contact Us
Contact Us

Email Us

Get in touch today to discover the right solutions for you.

Call Us

We are pleased to speak with you during our standard business hours.

U.S. Toll-Free only
+1 866 267 4479

For international call please find a number in our toll-free list.

IQVIA Institute Inquiries

We are ready to help you better understand and benefit from the work of the IQVIA Institute for Human Data Science. Please get in touch today to learn more.